Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Thrombocytopenia 5Lymphoma, Non-Hodgkin 5Hodgkin Disease 3Purpura, Thrombocytopenic, Idiopathic 2Purpura, Thrombocytopenic 2Neoplasms 2Multiple Myeloma 2Pancreatic Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, Monocytic, Acute 1Leukemia, Lymphoid 1Hematologic Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cytarabine 58Etoposide 24Daunorubicin 22Filgrastim 18Idarubicin 16Mitoxantrone 13Busulfan 13tipifarnib 11fludarabine phosphate 10Gemtuzumab 10Cyclophosphamide 10Peripheral Blood Stem Cell Transplantation 9Flow Cytometry 9sargramostim 8Clofarabine 8Methotrexate 7Gene Expression Profiling 7Cyclosporine 7Topotecan 6Azacitidine 6valspodar 5alvocidib 5Granulocyte Colony-Stimulating Factor 5Antilymphocyte Serum 5aldesleukin 4Radiotherapy 4Observation 4Bortezomib 4Arsenic Trioxide 4Vorinostat 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Monocytic, Acute × romiplostim × Clear all
NCT02046291 2021-06-08

Safety of Romiplostim (Nplate®) Following UCBT

Masonic Cancer Center, University of Minnesota

Phase 1 Completed
21 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoid, Leukemia, Monocytic, Acute, Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡